Chicago Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $80.6M | Buy |
87,582
+8,870
| +11% | +$8.99M | 2.17% | 14 |
|
|
2025
Q4 | $84.6M | Buy |
78,712
+756
| +1% | +$723K | 2.09% | 14 |
|
|
2025
Q3 | $59.5M | Sell |
77,956
-13,482
| -15% | -$10M | 1.46% | 23 |
|
|
2025
Q2 | $71.3M | Buy |
91,438
+5,807
| +7% | +$4.51M | 1.76% | 21 |
|
|
2025
Q1 | $70.7M | Buy |
85,631
+47,109
| +122% | +$39.2M | 2% | 15 |
|
|
2024
Q4 | $29.7M | Buy |
38,522
+11,709
| +44% | +$9.7M | 0.79% | 40 |
|
|
2024
Q3 | $23.8M | Sell |
26,813
-112
| -0.4% | -$101K | 0.66% | 41 |
|
|
2024
Q2 | $24.4M | Buy |
26,925
+64
| +0.2% | +$51.2K | 0.72% | 40 |
|
|
2024
Q1 | $20.9M | Buy |
26,861
+666
| +3% | +$474K | 0.64% | 41 |
|
|
2023
Q4 | $15.3M | Buy |
26,195
+6,040
| +30% | +$3.53M | 0.55% | 42 |
|
|
2023
Q3 | $10.8M | Sell |
20,155
-1,159
| -5% | -$597K | 0.51% | 44 |
|
|
2023
Q2 | $10M | Sell |
21,314
-610
| -3% | -$256K | 0.45% | 43 |
|
|
2023
Q1 | $7.53M | Buy |
21,924
+126
| +0.6% | +$42.5K | 0.37% | 50 |
|
|
2022
Q4 | $7.97M | Sell |
21,798
-30
| -0.1% | -$10.6K | 0.44% | 51 |
|
|
2022
Q3 | $7.06M | Hold |
21,828
| – | – | 0.41% | 51 |
|
|
2022
Q2 | $7.08M | Buy |
21,828
+50
| +0.2% | +$15K | 0.39% | 51 |
|
|
2022
Q1 | $6.24M | Hold |
21,778
| – | – | 0.27% | 57 |
|
|
2021
Q4 | $6.02M | Sell |
21,778
-54
| -0.2% | -$13.7K | 0.22% | 59 |
|
|
2021
Q3 | $5.04M | Hold |
21,832
| – | – | 0.19% | 59 |
|
|
2021
Q2 | $5.01M | Buy |
21,832
+498
| +2% | +$100K | 0.2% | 58 |
|
|
2021
Q1 | $3.99M | Buy |
21,334
+87
| +0.4% | +$17K | 0.17% | 59 |
|
|
2020
Q4 | $3.59M | Sell |
21,247
-10
| -0% | -$1.49K | 0.16% | 65 |
|
|
2020
Q3 | $3.15M | Hold |
21,257
| – | – | 0.16% | 65 |
|
|
2020
Q2 | $3.49M | Hold |
21,257
| – | – | 0.2% | 60 |
|
|
2020
Q1 | $2.95M | Sell |
21,257
-2,490
| -10% | -$342K | 0.24% | 59 |
|
|
2019
Q4 | $3.12M | Sell |
23,747
-100
| -0.4% | -$11.6K | 0.19% | 62 |
|
|
2019
Q3 | $2.67M | Hold |
23,847
| – | – | 0.18% | 66 |
|
|
2019
Q2 | $2.64M | Buy |
23,847
+1,000
| +4% | +$118K | 0.17% | 67 |
|
|
2019
Q1 | $2.96M | Sell |
22,847
-822
| -3% | -$100K | 0.2% | 65 |
|
|
2018
Q4 | $2.74M | Buy |
23,669
+200
| +0.9% | +$22.3K | 0.22% | 62 |
|
|
2018
Q3 | $2.52M | Hold |
23,469
| – | – | 0.17% | 60 |
|
|
2018
Q2 | $2M | Buy |
23,469
+705
| +3% | +$57.9K | 0.16% | 71 |
|
|
2018
Q1 | $1.76M | Buy |
+22,764
| New | +$1.83M | 0.24% | 60 |
|
Other funds holding LLY
VCM
VPM
Chicago Capital's LLY Position: Q1 2026 in Review
Chicago Capital increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $8.99M and bringing the position to 87,582 shares worth $80.6M. The position accounts for 2.17% of the portfolio, ranked #14.
Chicago Capital first reported a position in LLY in Q1 2018 and has held it in 33 quarters since. The position peaked at $84.6M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Chicago Capital held 87,582 shares of Eli Lilly worth $80.6M as of Q1 2026.
- Chicago Capital bought 8,870 Eli Lilly shares in Q1 2026, an estimated $8.99M.
- Eli Lilly made up 2.17% of Chicago Capital's portfolio in Q1 2026, its #14 holding.
- Chicago Capital first reported a position in Eli Lilly in Q1 2018 and has held it in 33 quarters since.
- Chicago Capital's Eli Lilly position peaked at $84.6M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Chicago Capital's 13F filing for Q1 2026, filed 24 Apr 2026.